Advertisement

Topics

Vertex Release: FDA Approves KALYDECO (Ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Vertex Release: FDA Approves KALYDECO (Ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

NEXT ARTICLE

More From BioPortfolio on "Vertex Release: FDA Approves KALYDECO (Ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations"

Quick Search
Advertisement